| [1] | Sung H , Ferlay J , Siegel RL , Laversanne M , Soerjomataram I , Jemal A , et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209-249 |
| [2] | Torre LA , Bray F , Siegel RL , Ferlay J , Lortet-Tieulent J , Jemal A . Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108 |
| [3] | Josep ML , Jessica ZR , Eli P , Bruno S , Myron S , Morris S , et al . Hepatocellular carcinoma. Nat Rev Dis Primers 2016; 14: 16018 |
| [4] | Westwood M , Joore M , Grutters J , Redekop K , Armstrong N , Lee K , et al . Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis. Health Technol Assess 2013; 17: 1-243 |
| [5] |
Tanaka H , Iijima H , Nouso K , Aoki N , Iwai T , Takashima T , et al . Cost-effectiveness analysis on the surveillance for hepatocellular carcinoma in liver cirrhosis patients using contrast-enhanced ultrasonography. Hepatol Res 2012; 42: 376-384.
doi: 10.1111/j.1872-034X.2011.00936.x |
| [6] |
Smajerova M , Petrasova H , Little J , Ovesna P , Andrasina T , Valek V , et al . Contrast-enhanced ultrasonography in the evaluation of incidental focal liver lesions: a cost-effectiveness analysis. World J Gastroenterol 2016; 22: 8605-8614.
doi: 10.3748/wjg.v22.i38.8605 |
| [7] |
Streb JW , Tchelepi H , Malhi H , Deurdulian C , Grant EG . Retrospective analysis of contrast-enhanced ultrasonography effectiveness in reducing time to diagnosis and imaging-related expenditures at a single large United States county hospital. Ultrasound Q 2019; 35: 99-102.
doi: 10.1097/RUQ.0000000000000375 |
| [8] |
Mandai M , Koda M , Matono T , Nagahara T , Sugihara T , Ueki M , et al . Assessment of hepatocellular carcinoma by contrast-enhanced ultrasound with perfluorobutane microbubbles: comparison with dynamic CT. Br J Radiol 2011; 84: 499-507.
doi: 10.1259/bjr/38682601 |
| [9] |
Ding J , Long L , Zhang X , Chen C , Zhou H , Zhou Y , et al . Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS. Eur Radiol 2021; 31: 847-854.
doi: 10.1007/s00330-020-07159-z |
| [10] |
Huang Z , Zhou P , Li S , Li K . MR versus CEUS LI-RADS for distinguishing hepatocellular carcinoma from other hepatic malignancies in high-risk patients. Ultrasound Med Biol 2021; 47: 1244-1252.
doi: 10.1016/j.ultrasmedbio.2021.01.020 |
| [11] | Hu J , Burrowes DP , Caine BA , Gibson N , Bhayana D , Medellin A , et al. Nodules identified on surveillance ultrasound for HCC: CEUS or MRI as the initial test? J Ultrasound Med 2023; 42:1181-1190. |
| [12] |
Burak KW , Douglas L , Congly SE . Comparing magnetic resonance imaging and Contrast-enhanced ultrasound (CEUS) for the characterization of nodules found on hepatocellular carcinoma surveillance: CEUS is our clear choice. J Ultrasound Med 2023; 42: 1175-1180.
doi: 10.1002/jum.16200 |
| [13] | American College of Radiology. LI-RADS® CEUS v2017 |American College of Radiology. https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/CEUS-LI-RADS-2017-Core.pdf. |
| [14] |
Wilson SR , Lyshchik A , Piscaglia F , Cosgrove D , Jang HJ , Sirlin C , et al . CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI. Abdom Radiol (NY) 2018; 43: 127-142.
doi: 10.1007/s00261-017-1250-0 |
| [15] |
Hai Y , Savsani E , Chong W , Eisenbrey J , Lyshchik A . Meta-analysis and systematic review of contrast-enhanced ultrasound in evaluating the treatment response after locoregional therapy of hepatocellular carcinoma. Abdom Radiol (NY) 2021; 46: 5162-5179.
doi: 10.1007/s00261-021-03248-9 |
| [16] | Zhang S , Yue M , Shu R , Cheng H , Hu P . Recent advances in the management of hepatocellular carcinoma. J BUON 2016; 21: 307-311 |
| [17] |
Ganesan P , Kulik LM . Hepatocellular carcinoma: new developments. Clin Liver Dis 2023; 27: 85-102.
doi: 10.1016/j.cld.2022.08.004 |
| [18] |
Cho Y , Choi JW , Kwon H , Kim KY , Lee BC , Chu HH , et al . Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean liver cancer association. Korean J Radiol 2023; 24: 606-625.
doi: 10.3348/kjr.2023.0385 |
| [19] |
European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatocellular carcinoma. J Hepatol 2025; 82: 315-374.
doi: 10.1016/j.jhep.2024.08.028 |
| [20] |
Song JE , Kim DY . Conventional vs drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma. World J Hepatol 2017; 9: 808-814.
doi: 10.4254/wjh.v9.i18.808 |
| [21] |
Gaba RC , Lokken RP , Hickey RM , Lipnik AJ , Lewandowski RJ , Salem R , et al . Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic malignancy. Journal of Vascular and Interventional Radiology 2017; 28: 1210-1223.
doi: 10.1016/j.jvir.2017.04.025 |
| [22] |
Dietrich CF , Lorentzen T , Appelbaum L , Buscarini E , Cantisani V , Correas JM , et al . EFSUMB guidelines on interventional ultrasound (INVUS), Part III-abdominal treatment procedures (short version). Ultraschall Med 2016; 37: 27-45.
doi: 10.1055/s-0035-1553965 |
| [23] |
Martin RCG 2nd , Woeste M , Egger ME , Scoggins CR , McMasters KM , Philips P . Patient selection and outcomes of laparoscopic microwave ablation of hepatocellular carcinoma. Cancers (Basel) 2023; 15: 1965.
doi: 10.3390/cancers15071965 |
| [24] |
Savsani E , Shaw CM , Forsberg F , Wessner CE , Lyshchik A , O'Kane P , et al . Contrast-enhanced US evaluation of hepatocellular carcinoma response to chemoembolization: a prospective multicenter trial. Radiology 2023; 309: e230727.
doi: 10.1148/radiol.230727 |
| [25] |
Cerrito L , Ainora ME , Cuccia G , Galasso L , Mignini I , Esposto G , et al . Dynamic contrast-enhanced ultrasound in the prediction of advanced hepatocellular carcinoma response to systemic and locoregional therapies. Cancers (Basel) 2024; 16: 551.
doi: 10.3390/cancers16030551 |
| [26] |
Eisenbrey JR , Gabriel H , Savsani E , Lyshchik A . Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies. Abdom Radiol (NY) 2021; 46: 3579-3595.
doi: 10.1007/s00261-021-03059-y |
| [27] |
Lyshchik A , Fetzer DT , Kono Y , Wilson SR , Dietrich CF , Clevert DA , et al . Liver imaging reporting and data system contrast-enhanced US nonradiation treatment response assessment version 2024. Radiology 2024; 311: e232369.
doi: 10.1148/radiol.232369 |
| [28] |
Kuon Yeng Escalante CM , Siu Xiao T , Nagaraj RU , Savsani E , Mohammed A , Li J , et al . Evaluation of the contrast-enhanced ultrasound nonradiation treatment response assessment LI-RADS v2024 using data from a multi-center transarterial chemoembolization study. Acad Radiol 2024; 31: 5078-5086.
doi: 10.1016/j.acra.2024.06.005 |
| [29] |
Cao J , Dong Y , Xu X , Zhang Q , Wang W , Möller K , et al . LI-RADS CEUS nonradiation TRA version 2024: application on HCC patients treated with ablation treatment. Ultrasound Med Biol 2025; 51: 1308-1315.
doi: 10.1016/j.ultrasmedbio.2025.04.018 |
| [30] |
Llovet JM , Real MI , Montaña X , Planas R , Coll S , Aponte J , et al . Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739.
doi: 10.1016/S0140-6736(02)08649-X |
| [31] |
Lo CM , Ngan H , Tso WK , Liu CL , Lam CM , Poon RT , et al . Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171.
doi: 10.1053/jhep.2002.33156 |
| [32] |
Llovet JM , Bruix J . Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-442.
doi: 10.1053/jhep.2003.50047 |
| [33] |
Lammer J , Malagari K , Vogl T , Pilleul F , Denys A , Watkinson A , et al . Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52.
doi: 10.1007/s00270-009-9711-7 |
| [34] | Razi M , Jianping G , Xu H , Ahmed MJ . Conventional versus drug-eluting bead transarterial chemoembolization: a better option for treatment of unresectable hepatocellular carcinoma. J Interv Med 2020; 4: 11-14 |
| [35] |
Kloeckner R , Weinmann A , Prinz F , Santos DPD , Ruckes C , Duebr C , et al . Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer 2015; 15: 465.
doi: 10.1186/s12885-015-1480-x |
| [36] | Guiu B , Deschamps F , Aho S , Munck F , Dromain C , Boige V , et al . Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol 2012; 56: 609-617 |
| [37] |
Monier A , Guiu B , Duran R , Aho S , Bize P , Deltenre P , et al . Liver and biliary damages following transarterial chemoembolization of hepatocellular carcinoma: comparison between drug-eluting beads and lipiodol emulsion. Eur Radiol 2017; 27: 1431-1439.
doi: 10.1007/s00330-016-4488-y |
| [38] |
Sacco R , Bargellini I , Bertini M , Bozzi E , Romano A , Petruzzi P , et al . Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2011; 22: 1545-1552.
doi: 10.1016/j.jvir.2011.07.002 |
| [39] |
Facciorusso A , Di Maso M , Muscatiello N . Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. Dig Liver Dis 2016; 48: 571-577.
doi: 10.1016/j.dld.2016.02.005 |
| [40] |
Cucchetti A , Trevisani F , Cappelli A , Mosconi C , Renzulli M , Pinna AD , et al . Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. Dig Liver Dis 2016; 48: 798-805.
doi: 10.1016/j.dld.2016.03.031 |
| [41] |
Roth GS , Benhamou M , Teyssier Y , Seigneurin A , Abousalihac M , Sengel C , et al . Comparison of trans-arterial chemoembolization and bland embolization for the treatment of hepatocellular carcinoma: a propensity score analysis. Cancers (Basel) 2021; 13: 812.
doi: 10.3390/cancers13040812 |
| [42] |
Tsochatzis EA , Fatourou E , O'Beirne J , Meyer T , Burroughs AK . Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol 2014; 20: 3069-3077.
doi: 10.3748/wjg.v20.i12.3069 |
| [43] |
Xie ZB , Ma L , Wang XB , Bai T , Ye JZ , Zhong JH , et al . Transarterial embolization with or without chemotherapy for advanced hepatocellular carcinoma: a systematic review. Tumour Biol 2014; 35: 8451-8459.
doi: 10.1007/s13277-014-2340-z |
| [44] |
Facciorusso A , Bellanti F , Villani R , Salvatore V , Muscatiello N , Piscaglia F , et al . Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: a meta-analysis of randomized trials. United European Gastroenterol J 2017; 5: 511-518.
doi: 10.1177/2050640616673516 |
| [45] |
Cathomas M , Mueller F , Mertineit N , Baumgartner I , Candinas D , Berzigotti A , et al . Comparison of transarterial bland embolization and drug-eluting beads transarterial chemoembolization for very early and early hepatocellular carcinoma not amenable for surgery or ablation: a single center retrospective data analysis. J Gastrointest Oncol 2023; 14: 2167-2177.
doi: 10.21037/jgo-23-261 |
| [46] |
Hidaka T , Anai H , Sakaguchi H , Sueyoshi S , Tanaka T , Yamamoto K , et al . Efficacy of combined bland embolization and chemoembolization for huge (≥ 10 cm) hepatocellular carcinoma. Minim Invasive Ther Allied Technol 2021; 30: 221-228.
doi: 10.1080/13645706.2020.1725580 |
| [47] |
Ding H , Kudo M , Onda H , Suetomi Y , Minami Y , Chung H , et al . Evaluation of posttreatment response of hepatocellular carcinoma with contrast-enhanced coded phase-inversion harmonic US: comparison with dynamic CT. Radiology 2001; 221: 721-730.
doi: 10.1148/radiol.2213010358 |
| [48] | Takizawa K , Numata K , Morimoto M , Kondo M , Nozaki A , Moriya S , et al. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma. Eur J Radiol 2013; 82:1471-1480. |
| [49] |
Watanabe Y , Ogawa M , Kumagawa M , Hirayama M , Miura T , Matsumoto N , et al . Utility of contrast-enhanced ultrasound for early therapeutic evaluation of hepatocellular carcinoma after transcatheter arterial chemoembolization. J Ultrasound Med 2020; 39: 431-440.
doi: 10.1002/jum.15118 |
| [50] |
Shaw CM , Eisenbrey JR , Lyshchik A , O'Kane PL , Merton DA , Machado P , et al . Contrast-enhanced ultrasound evaluation of residual blood flow to hepatocellular carcinoma after treatment with transarterial chemoembolization using drug-eluting beads: a prospective study. J Ultrasound Med 2015; 34: 859-867.
doi: 10.7863/ultra.34.5.859 |
| [51] |
Shiozawa K , Matsui T , Murakami T , Watanabe M , Maetani I . Predicting therapeutic efficacy of transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma using contrast-enhanced ultrasound. Diagnostics (Basel) 2021; 11: 291.
doi: 10.3390/diagnostics11020291 |
| [52] |
Forner A , Reig M , Bruix J . Hepatocellular carcinoma. Lancet 2018; 391: 1301-1314.
doi: 10.1016/S0140-6736(18)30010-2 |
| [53] |
Head HW , Dodd GD 3rd . Thermal ablation for hepatocellular carcinoma. Gastroenterology 2004; 127: S167-178.
doi: 10.1053/j.gastro.2004.09.031 |
| [54] |
Kim YS , Lim HK , Rhim H , Lee MW . Ablation of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2014; 28: 897-908.
doi: 10.1016/j.bpg.2014.08.011 |
| [55] |
Cucchetti A , Piscaglia F , Cescon M , Colecchia A , Ercolani G , Bolondi L , et al . Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol 2013; 59: 300-307.
doi: 10.1016/j.jhep.2013.04.009 |
| [56] |
Faccia M , Garcovich M , Ainora ME , Riccardi L , Pompili M , Gasbarrini A , et al . Contrast-enhanced ultrasound for monitoring treatment response in different stages of hepatocellular carcinoma. Cancers (Basel) 2022; 14: 481.
doi: 10.3390/cancers14030481 |
| [57] |
Bale R , Schullian P , Eberle G , Putzer D , Zoller H , Schneeberger S , et al . Stereotactic radiofrequency ablation of hepatocellular carcinoma: a histopathological study in explanted livers. Hepatology 2019; 70: 840-850.
doi: 10.1002/hep.30406 |
| [58] |
Izzo F , Granata V , Grassi R , Fusco R , Palaia R , Delrio P , et al . Radiofrequency ablation and microwave ablation in liver tumors: an update. Oncologist 2019; 24: e990-e1005.
doi: 10.1634/theoncologist.2018-0337 |
| [59] |
Lu MD , Xu HX , Xie XY , Yin XY , Chen JW , Kuang M , et al . Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. J Gastroenterol 2005; 40: 1054-1060.
doi: 10.1007/s00535-005-1671-3 |
| [60] |
Fu Y , Zhu Q , Zhao X , Lu J , Wang W . Efficacy and safety of ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma at specific anatomic sites of the liver: a systematic review and meta-analysis. BMC Gastroenterol 2025; 25: 505.
doi: 10.1186/s12876-025-04081-w |
| [61] |
Yu Q , Liu C , Navuluri R , Ahmed O . Percutaneous microwave ablation versus radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Abdom Radiol (NY) 2021; 46: 4467-4475.
doi: 10.1007/s00261-021-03080-1 |
| [62] | Tan W , Deng Q , Lin S , Wang Y , Xu G . Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia 2019; 36: 264-272 |
| [63] |
Potretzke TA , Ziemlewicz TJ , Hinshaw JL , Lubner MG , Wells SA , Brace CL , et al . Microwave versus radiofrequency ablation treatment for hepatocellular carcinoma: a comparison of efficacy at a single center. J Vasc Interv Radiol 2016; 27: 631-638.
doi: 10.1016/j.jvir.2016.01.136 |
| [64] |
Sun B , Zhang W , Chen L , Sun T , Ren Y , Zhu L , et al . The safety and efficacy of percutaneous ethanol injection in the treatment of tumor thrombus in advanced hepatocellular carcinoma with portal vein tumor thrombus. Abdom Radiol (NY) 2022; 47: 858-868.
doi: 10.1007/s00261-021-03349-5 |
| [65] |
Ebara M , Okabe S , Kita K , Sugiura N , Fukuda H , Yoshikawa M , et al . Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol 2005; 43: 458-564.
doi: 10.1016/j.jhep.2005.03.033 |
| [66] | Pompili M , Nicolardi E , Abbate V , Miele L , Riccardi L , Covino M , et al . Ethanol injection is highly effective for hepatocellular carcinoma smaller than 2 cm. World J Gastroenterol 2011; 17: 3126-3132 |
| [67] |
Salvaggio G , Campisi A , Lo Greco V , Cannella I , Meloni MF , Caruso G . Evaluation of posttreatment response of hepatocellular carcinoma: comparison of ultrasonography with second-generation ultrasound contrast agent and multidetector CT. Abdom Imaging 2010; 35: 447-453.
doi: 10.1007/s00261-009-9551-6 |
| [68] |
Wiggermann P , Zuber-Jerger I , Zausig Y , Loss M , Scherer MN , Schreyer AG , et al . Contrast-enhanced ultrasound improves real-time imaging of ablation region during radiofrequency ablation: preliminary results. Clin Hemorheol Microcirc 2011; 49: 43-54.
doi: 10.3233/CH-2011-1456 |
| [69] |
Gallotti A , D'Onofrio M , Ruzzenente A , Martone E , De Robertis R , Guglielmi A , et al . Contrast-enhanced ultrasonography (CEUS) immediately after percutaneous ablation of hepatocellular carcinoma. Radiol Med 2009; 114: 1094-1105.
doi: 10.1007/s11547-009-0436-0 |
| [70] |
Ainora ME , Iezzi R , Ponziani FR , Garcovich M , Di Stasio E , Riccardi L , et al . Contrast-enhanced ultrasound in the short-term evaluation of hepatocellular carcinoma after locoregional treatment. Dig Dis 2020; 38: 522-533.
doi: 10.1159/000506455 |
| [71] |
Bartolotta TV , Taibbi A , Midiri M , De Maria M . Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound. Abdom Imaging 2008; 33: 501-511.
doi: 10.1007/s00261-007-9294-1 |
| [72] | Pregler B , Beyer LP , Wiesinger I , Nießen C , Jung EM , Stroszczynski C , et al . Microwave ablation of large HCC lesions: added value of CEUS examinations for ablation success control. Clin Hemorheol Microcirc 2016; 64: 483-490 |
| [73] |
Qu P , Yu X , Liang P , Cheng Z , Han Z , Liu F , et al . Contrast-enhanced ultrasound in the characterization of hepatocellular carcinomas treated by ablation: comparison with contrast-enhanced magnetic resonance imaging. Ultrasound Med Biol 2013; 39: 1571-1579.
doi: 10.1016/j.ultrasmedbio.2013.03.030 |
| [74] |
Lu MD , Yu XL , Li AH , Jiang TA , Chen MH , Zhao BZ , et al . Comparison of contrast enhanced ultrasound and contrast enhanced CT or MRI in monitoring percutaneous thermal ablation procedure in patients with hepatocellular carcinoma: a multi-center study in China. Ultrasound Med Biol 2007; 33: 1736-1749.
doi: 10.1016/j.ultrasmedbio.2007.05.004 |
| [75] |
Du J , Li HL , Zhai B , Chang S , Li FH . Radiofrequency ablation for hepatocellular carcinoma: utility of conventional ultrasound and contrast-enhanced ultrasound in guiding and assessing early therapeutic response and short-term follow-up results. Ultrasound Med Biol 2015; 41: 2400-2411.
doi: 10.1016/j.ultrasmedbio.2015.05.004 |
| [76] |
Catalano O , Izzo F , Vallone P , Sandomenico F , Albino V , Nunziata A , et al . Integrating contrast-enhanced sonography in the follow-up algorithm of hepatocellular carcinoma treated with radiofrequency ablation: single cancer center experience. Acta Radiol 2015; 56: 133-142.
doi: 10.1177/0284185114521108 |
| [77] |
Kim TK , Khalili K , Jang HJ . Local ablation therapy with contrast-enhanced ultrasonography for hepatocellular carcinoma: a practical review. Ultrasonography 2015; 34: 235-245.
doi: 10.14366/usg.15018 |
| [78] |
Dong J , Hu X , Li L , Jing FY , Chen JJ , Chen J . Diagnostic performance of contrast-enhanced ultrasonography for predicting therapeutic response to radiofrequency ablation in patients with hepatocellular carcinoma: a meta-analysis. Discov Oncol 2025; 16: 1237.
doi: 10.1007/s12672-025-03008-x |
| [79] |
Zheng SG , Xu HX , Lu MD , Xie XY , Xu ZF , Liu GJ , et al . Role of contrast-enhanced ultrasound in follow-up assessment after ablation for hepatocellular carcinoma. World J Gastroenterol 2013; 19: 855-865.
doi: 10.3748/wjg.v19.i6.855 |
| [80] | Long H , Zhou X , Zhang X , Ye J , Huang T , Cong L , et al . 3D fusion is superior to 2D point-to-point contrast-enhanced US to evaluate the ablative margin after RFA for hepatocellular carcinoma. Eur Radiol 2024; 34: 1247-1257 |
| [81] |
Lu YB , Huang YN , Weng YC , Chiang TY , Fang TK , Chen WT , et al . Contrast-enhanced ultrasonography guidance avoids US-CT/MR fusion error for percutaneous radiofrequency ablation of hepatocellular carcinoma. BMC Med Imaging 2024; 24: 323.
doi: 10.1186/s12880-024-01508-w |
| [82] |
Ye J , Huang G , Zhang X , Xu M , Zhou X , Lin M , et al . Three-dimensional contrast-enhanced ultrasound fusion imaging predicts local tumor progression by evaluating ablative margin of radiofrequency ablation for hepatocellular carcinoma: a preliminary report. Int J Hyperthermia 2019; 36: 55-64.
doi: 10.1080/02656736.2018.1530460 |
| [83] |
Wang Y , Jing X , Ding J . Clinical value of dynamic 3-dimensional contrast-enhanced ultrasound imaging for the assessment of hepatocellular carcinoma ablation. Clin Imaging 2016; 40: 402-406.
doi: 10.1016/j.clinimag.2015.11.022 |
| [84] |
Delaney LJ , Tantawi M , Wessner CE , Machado P , Forsberg F , Lyshchik A , et al . Predicting long-term hepatocellular carcinoma response to transarterial radioembolization using contrast-enhanced ultrasound: initial experiences. Ultrasound Med Biol 2021; 47: 2523-2531.
doi: 10.1016/j.ultrasmedbio.2021.05.006 |
| No related articles found! |
|
||